



Akerro Therapeutics to Present at Upcoming Healthcare Conferences in September

August 31, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akerro Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month:

- Morgan Stanley Annual Global Healthcare Conference: Fireside chat on Tuesday, September 12 at 4:55 p.m. ET
- H. C. Wainwright 25th Annual Global Investment Conference: Fireside chat on Wednesday, September 13 at 9:00 a.m. ET

Live webcasts of the Company presentations will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akerro Therapeutics

Akerro Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies. Akerro's lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX has also been evaluated in an expansion cohort of the SYMMETRY study, Cohort D, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes, for which topline results were reported on June 5, 2023. Akerro is headquartered in South San Francisco. Visit us at akerotx.com and follow us on [LinkedIn](#) and [Twitter](#) for more information.

Investor Contact:

Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:

Sarah O'Connell
Verge Scientific Communications
732.456.0092
soconnell@vergescientific.com